Somatic mutations in cytosolic or mitochondrial isoforms of isocitrate dehydrogenase (IDH1 or IDH2, respectively) contribute to oncogenesis via production of the metabolite 2hydroxyglutarate (2HG). Isoform-selective IDH inhibitors suppress 2HG production and induce clinical responses in patients with IDH1-and IDH2-mutant malignancies. Despite the promising activity of IDH inhibitors, the mechanisms that mediate resistance to IDH inhibition are poorly understood. Here, we describe four clinical cases that identify mutant IDH isoform switching, either from mutant IDH1 to mutant IDH2 or vice versa, as a mechanism of acquired clinical resistance to IDH inhibition in solid and liquid tumors.
Introduction
Somatic mutations in isocitrate dehydrogenase (IDH) enzymes are observed in a wide spectrum of human cancers, most commonly gliomas 1,2 , myeloid malignancies 3 , chondrosarcomas 4 , and intrahepatic cholangiocarcinomas (ICC) 5 . IDH enzymes normally function as components of the tricarboxylic acid cycle, catalyzing the interconversion of isocitrate and alpha-ketoglutarate (αKG) 6 . Cancer-associated IDH mutations occur at catalytic-site arginine residues in cytoplasmic IDH1 (R132) and mitochondrial IDH2 (R140 and R172), altering the enzymatic activity to promote efficient reduction of αKG to the 'oncometabolite' 2-hydroxyglutarate (2HG) 7, 8 . Cellular accumulation of 2HG inhibits αKG-dependent dioxygenases that mediate histone and DNA demethylation, leading to a repressive chromatin landscape that disrupts normal cellular differentiation and contributes to oncogenesis [9] [10] [11] [12] .
Importantly, the effects of 2HG on chromatin and cell differentiation are largely reversible 11 , therefore drugs that inhibit 2HG production by mutant IDH represent potential therapies for IDH-mutant malignancies 13 . Small-molecule inhibitors of IDH1 or IDH2 inhibit 2HG production by IDH-mutant enzymes, induce cellular differentiation, and inhibit cancer growth in preclinical models 6, 13 . In phase I/II trials, the mutant IDH1 inhibitor ivosidenib (AG-120) and the mutant IDH2 inhibitor enasidenib (AG-221) induced clinical responses in patients with relapsed/refractory IDH-mutant myeloid malignancies 14, 15 . Clinical trials with ivosidenib are underway for the treatment of relapsed/refractory IDH1-mutant solid tumors, including glioma, ICC, and chondrosarcoma 16 .
The mechanisms that mediate response and resistance to small-molecule IDH inhibition remain poorly understood [17] [18] [19] . Here, we identify mutant IDH isoform switching, either from cytoplasmic mutant IDH1 to mitochondrial mutant IDH2 or vice versa, as a mechanism of acquired clinical resistance to IDH inhibition. The first two cases describe patients with relapsed/refractory IDH1 R132C-mutant AML who achieved durable remissions in response to the mutant IDH1 inhibitor ivosidenib followed by leukemic progression on therapy, rise of blood 2HG levels, and emergence of new IDH2 R140Q mutations. The third case describes a patient with treatment-refractory IDH1 R132C-mutant intrahepatic cholangiocarcinoma who attained a sustained partial response to ivosidenib followed by progression of disease associated with acquisition of a new IDH2 R172V mutation. The fourth case describes a patient with relapsed/refractory IDH2 R140Q-mutant acute myeloid leukemia who achieved a durable remission to the mutant IDH2 inhibitor enasidenib, followed by progression on therapy associated with emergence of a new IDH1 R132C mutation that was sensitive to combined IDH1/2 blockade with AG-881. These findings provide evidence of selective pressure to maintain 2HG production in IDH-mutant malignancies, as well as suggest potential strategies for disease monitoring and therapies that might overcome acquired resistance to IDH inhibition.
Results

Case Reports 1 and 2
A 54-year-old man with normal karyotype AML relapsed 100 days after allogeneic bone marrow transplantation with progressive pancytopenia and a bone marrow biopsy showing 30% leukemic blasts ( Figures 1A and B ). Targeted NGS of bone marrow cells using a microdroplet-PCR assay 20 demonstrated the presence of an IDH1 R132C mutation and two DNMT3A mutations ( Figure 1C and Supplementary Tables 1 and 4 ). The patient began treatment with ivosidenib 500 mg orally daily, with a complete remission evident after three 28-day cycles of therapy. After completing twelve 28-day cycles of ivosidenib, the blast count and blood 2HG levels began to rise and a new IDH2 R140Q mutation was detected (Figures 1A, C, D).
Ivosidenib was discontinued and enasidenib was started. After several days of treatment with enasidenib, the patient developed fevers and hypoxia suspected to be secondary to IDH inhibitor differentiation syndrome 21 ; enasidenib was discontinued.
A 72-year-old man presented with AML arising from pre-existing JAK2 V617F-mutant myelofibrosis. For several years prior, the myelofibrosis had been treated successfully with single-agent ruxolitinib, then combination therapy with ruxolitinib plus decitabine. However, at the time of presentation with secondary AML, there were 37% blasts in the bone marrow and the patient was neutropenic (Figures 1E and F) . Targeted NGS of bone marrow mononuclear cells using a microdroplet-PCR assay 20 demonstrated the presence of JAK2 V617F and IDH1 R132C mutations ( Figure 1G ), as well as mutations in ASXL1, EZH2, and RUNX1
( Supplementary Tables 1 and 5 ). The patient began treatment with ivosidenib 500 mg orally daily, and a complete response was evident after one 28-day cycle of therapy. The IDH1 mutation became undetectable after four 28-day cycles of ivosidenib, but then reappeared after the eighth 28-day cycle ( Figure 1G ). The patient remained in complete morphologic remission until the start of the twelfth cycle when the bone marrow blasts increased to 12% then 28% four weeks later ( Figure 1E ). The increase in AML blasts was associated with the emergence of a new IDH2 R140Q mutation and a rise in the serum 2HG levels ( Figures 1G and H) . Ivosidenib was discontinued and the patient subsequently pursued treatment with low-dose cytarabine and venetoclax 22 .
Case Report 3
A 79-year-old woman with AJCC Stage IV (T3N1M1) intrahepatic cholangiocarcinoma (ICC) presented for evaluation. One month prior to presentation she had developed anorexia, unintentional weight loss, and abdominal distention. Cross-sectional imaging with computed tomography revealed an 8x5x7.5 cm hypoattenuating mass with peripheral enhancement and capsular retraction in the right hepatic lobe, multiple hepatic satellite tumors, and extensive retroperitoneal lymphadenopathy. Core biopsy of the dominant right hepatic mass revealed a poorly differentiated adenocarcinoma with immunohistochemical markers consistent with a primary biliary tumor. An analysis of genomic DNA from the biopsy specimen using targeted NGS revealed an IDH1 R132C mutation and no other detectable mutations (Supplemental Tables 2 and 6 ).
After documented radiographic progression on multiple standard and investigational agents, the patient began treatment with ivosidenib 500 mg orally daily. Computed tomographic scans prior to treatment and then serially over the course of treatment demonstrated a partial response to treatment with a 50% decrease in disease burden (Figures 2A and B ). An escape lesion was identified at day 392, and this lesion continued to enlarge on a follow-up scan at day 446, despite a further decrease in size of the original tumor ( Figure 2B with an allelic fraction that decreased over the course of ivosidenib therapy ( Figure 2D ). In contrast, the IDH2 R172V mutation first became detectable at day 448 coinciding with radiographic disease progression ( Figure 2D ). Measurement of 2HG levels by liquid chromatography-mass spectrometry (LC-MS) demonstrated increased 2HG within the escape tumor lesion ( Figure S1A ). However, possibly due to the small size of this lesion, there was no detectable increase in plasma 2HG at the time of progression ( Figure S1B ). Introduction of the IDH2 R172V mutation into IDH1 R132C-mutant chondrosarcoma cells restored 2HG production that was resistant to ivosidenib, but susceptible to combined treatment with ivosidenib and enasidenib ( Figure S1C ).
Case Report 4
A previously healthy 70-year-old man was found to be pancytopenic on routine bloodwork. Bone marrow aspiration and core biopsy demonstrated a hypercellular marrow with dysplastic neutrophils, erythroid precursors, and megakaryocytes. Myeloblasts were increased and comprised 15% of the marrow cellularity. These morphologic findings were consistent with myelodysplastic syndrome (MDS), subtype refractory anemia with excess blasts 2 (RAEB-2). The patient began treatment with the mutant IDH2 inhibitor enasidenib 100 mg orally twice daily. Monthly bone marrow evaluation demonstrated a progressive decrease in the myeloid blast percentage with a complete response (blasts <5%) evident after completing three 28-day cycles of therapy ( Figures 3A and S2D ). Although the pancytopenia persisted, there was a modest improvement in the absolute neutrophil count ( Figures S2A-C) . The variant allele frequency (VAF) for IDH2 R140Q remained in the ~20-40% range ( Figure 3B ), consistent with the observation that enasidenib promotes differentiation of IDH2-mutant blasts rather than cytotoxicity 14, 17 . Serial measurements of plasma 2HG concentration demonstrated a decrease from the pre-treatment level of 6.2 µM to levels ranging from 0.5-1.5 µM while on therapy with enasidenib ( Figure 3C ).
The patient remained in complete remission until the start of cycle 17 of enasidenib (day 448), at which time the bone marrow blast percentage increased to 10% ( Figure 3A ), leukemic blasts appeared in the blood (not shown), and two CEBPA mutations became detectable by Table 7 ). On day 497, the dose of enasidenib was increased to 200 mg orally twice daily, resulting in a transient decrease in bone marrow blasts ( Figure 3A ). However, eight weeks later there was an increase in bone marrow blasts 
NGS of bone marrow cells (Supplementary
Discussion
We have identified mutant IDH isoform switching as a mechanism of acquired resistance to IDH-targeted therapy. Both IDH1 and IDH2 mutations are observed in liquid tumors, whereas in solid tumors IDH1 mutations vastly outnumber IDH2 mutations 6 . The biological underpinning for the preferential selection of cytosolic IDH1 mutation versus mitochondrial IDH2 mutation in different cancer types remains poorly understood. Experimental evidence suggests that the level of 2HG production can vary based on the subcellular location of the IDH mutation 23 . Our findings suggest that the selective pressure of inhibiting mutant IDH activity in one subcellular compartment might provide an advantage for malignant subclones that acquire unimpeded mutant IDH activity in another subcellular compartment. It is unclear whether the resistance alleles were acquired during the course of treatment or were present prior to treatment in a rare subclone that was below the limit of detection of the NGS and ddPCR assays. Although the variant allele frequencies of the IDH mutations raise the possibility that the IDH1 and IDH2 mutations might be acquired within the same subclone, single cell analysis will be required to delineate whether resistance is due to serial or parallel mutation acquisition. Likewise, it will be important to determine whether additional co-occurring genomic alterations might contribute to acquired resistance to IDH inhibition.
Mutant IDH isoform switching represents a mechanism of acquired resistance to isoform-selective IDH targeted therapy with therapeutic import. Experimental evidence demonstrated that a cancer cell line expressing both mutant IDH1 and mutant IDH2 exhibited 2HG production that was resistant to monotherapy, yet sensitive to combined inhibition of both isoforms ( Fig S1C) . The patient in Case Report 4 exhibited potent inhibition of 2HG production and a transient clinical response to the dual IDH1/2 inhibitor AG-881, although there was subsequent 2HG-independent disease progression resulting from unknown molecular mechanisms. Alternatively, a strategy of co-targeting of mutant IDH1 and IDH2 from the outset might delay or prevent resistance and should be explored in clinical trials. As larger numbers of patients with IDH-mutant malignancies are treated with isoform selective IDH inhibitors, it will be important to establish the frequency of isoform switching and to elucidate other mechanisms of de novo and acquired resistance [17] [18] [19] . These cases underscore the potential utility of serial NGS and 2HG measurement in patients treated with IDH inhibitors as means to monitor response, define resistance mechanisms, and inform treatment recommendations.
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Methods
Clinical specimens
The patients described were enrolled on the phase I/II studies NCT01915498 14 IMPACT TM hybrid capture 24 for cholangiocarcinoma as previously described (see Supplementary Tables 1-3 
for gene lists).
Cell-free DNA (cfDNA) isolation and sequencing
Whole blood was collected in 10-ml Cell-Free DNA BCT tubes (STRECK) and centrifuged at 800 g for 10 min at ambient temperature. Plasma was separated from red blood cells and then subjected to an additional centrifugation at 18,000 g for 10 min at ambient temperature. Cellfree plasma was aliquoted and stored at -80°C. Extraction of cfDNA was performed using a fully automated QIAGEN platform, QIAsymphony SP, and QIAsymphony DSP Virus/Pathogen Midi Kit (QIAGEN). This is a bead-based custom protocol, optimized to work with 3 ml of plasma as starting material. The extraction process includes lysis, binding, wash, and elution steps. The final product was a 60 µl elution of cfDNA with an average size ~170-200 bp. Quality and quantity of cfDNA were evaluated with automated electrophoresis using a fragment analyzer with high sensitivity genomic DNA analysis kit (Advanced Analytical). A mean 122 ng of cfDNA was isolated at each timepoint and analyzed for wildtype and mutant IDH1 and IDH2 alleles by droplet digital PCR.
Droplet digital PCR
An assay specific for each wildtype and mutant allele was designed and ordered through Biorad (IDH1 R132C: dHsaMDV2010053; IDH2 R172V: dHsaMDS874523342). Cycling conditions were tested to ensure optimal annealing/extension temperature as well as optimal separation of positive from empty droplets. All reactions were performed on a QX200 ddPCR System (Bio-Rad) and evaluated in technical duplicates. Reactions were partitioned into a median of ~16,000 droplets per well using the QX200 droplet generator and run on a 96-well thermal cycler. Plates were then analyzed with the QuantaSoft v1.7 to assess the number of droplets positive for mutant or wildtype DNA.
Cell culture and DNA constructs
The chondrosarcoma cell line JJ012 25 with an endogenous IDH1 R132C mutation was maintained at low passage number in high glucose DMEM with 10% FBS, glucose 25 mM, and glutamine 4 mM and split every 2-3 days before reaching confluence. Cultured cells repeatedly tested negative for mycoplasma throughout the experimental period. The IDH2 wildtype and R172V constructs were cloned by standard site-directed mutagenesis (Thermo) and Gibson Assembly (New England Biolabs) into pCDNA3.1 (Thermo) and verified by Sanger sequencing.
For transient transfection experiments, cells were transfected using polyethylenimine. Two days after transfection, cells were treated with DMSO, ivosidenib (50 nM), or ivosidenib (50 nM) plus enasidenib (50 nM) and then harvested for protein and metabolite analysis one day later.
Gel electrophoresis and western blotting
For denatured gel electrophoresis, cells were harvested in 1x RIPA buffer (Cell Signaling), centrifuged at 21,000 g at 4° C, and supernatants were collected. Cleared cell lysates were quantified by BCA assay (ThermoFisher) and normalized for total protein concentration.
Samples were separated by SDS-PAGE, transferred to nitrocellulose membranes (Life Technologies), blocked in 5% milk prepared in Tris buffered saline with 0.1% Tween 20 (TBST), incubated with primary antibodies overnight at 4° C then horseradish peroxidase (HRP)conjugated secondary antibodies (GE Healthcare; anti-mouse, NA931V, sheep, 1:5000; antirabbit, NA934V, donkey, 1:5000). After incubation with ECL (ThermoFisher or GE Healthcare), imaging was performed using the Amersham Imager 600 (GE Healthcare). Primary antibodies used included: anti-IDH1 (Proteintech, 12332-1-AP; rabbit; 1:1000), anti-IDH2 (Abcam, ab55271; mouse; 1:1000), and anti-vinculin (Sigma, V4505; mouse; 1:1000).
Metabolite extraction and analysis
Metabolites were extracted from plasma (100 µl) or cell cultures (6-well plates) with ice-cold 80:20 methanol:water containing 2 µM deuterated 2-hydroxyglutarate (D-2-hydroxyglutaric-2,3,3,4,4-d 5 acid; deuterated-2HG) as an internal standard. After overnight incubation at -80° C, plasma or cell extracts were sonicated and centrifuged at 21,000 g for 20 min at 4° C to precipitate protein. Extracts were then dried in an evaporator (Genevac EZ-2 Elite). Metabolites were resuspended by addition of 50 µl of methoxyamine hydrochloride (40 mg/ml in pyridine) and incubated at 30° C for 90 min with agitation. Metabolites were further derivatized by addition of 80 µl of N-methyl-N-(trimethylsilyl) trifluoroacetamide (MSTFA) + 1% 2,2,2-trifluoro-N-methyl-N-(trimethylsilyl)-acetamide, chlorotrimethylsilane (TCMS; Thermo Scientific) and 70 µl of ethyl acetate (Sigma) and incubated at 37° C for 30 min. Samples were diluted 1:2 with 200 µl of ethyl acetate, then analyzed using an Agilent 7890A GC coupled to Agilent 5975C mass selective detector. The GC was operated in splitless mode with constant helium carrier gas flow of 1 ml/min and with a HP-5MS column (Agilent Technologies). The injection volume was 1 µl and the GC oven temperature was ramped from 60° C to 290° C over 25 min. Peaks representing compounds of interest were extracted and integrated using MassHunter vB.08.00 (Agilent Technologies) and then normalized to both the internal standard (deuterated-2HG) peak area and plasma volume or protein content as applicable. Ions used for quantification of metabolite levels were 2HG m/z 247 (confirmatory ion m/z 349) and deuterated-2HG m/z 252 (confirmatory ion m/z 354). Peaks were manually inspected and verified relative to known spectra for each metabolite. Absolute metabolite quantitation was performed using an external calibration curve with deuterated-2HG internal standard and the resulting concentrations corrected for the total plasma volume extracted. For the patient with IDH1-mutant intrahepatic cholangiocarcinoma, plasma and tumor 2HG was measured using a qualified liquid chromatography-tandem mass spectrometry (LC-MS/MS) method with a lower limit of quantitation of 30 ng/ml for plasma or 100 ng/g for tumor as previously described 7 . 
